Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sofosbuvir | 1 | 2017 | 1 | 0.560 |
Why?
|
| Carbamates | 1 | 2017 | 5 | 0.560 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 11 | 0.560 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 32 | 0.540 |
Why?
|
| Antiviral Agents | 1 | 2017 | 112 | 0.520 |
Why?
|
| Genotype | 1 | 2017 | 456 | 0.510 |
Why?
|
| HIV Infections | 2 | 2021 | 159 | 0.490 |
Why?
|
| Judgment | 1 | 2021 | 31 | 0.370 |
Why?
|
| Transgender Persons | 1 | 2021 | 11 | 0.360 |
Why?
|
| Education, Pharmacy | 1 | 2021 | 115 | 0.320 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2018 | 18 | 0.300 |
Why?
|
| Aminoglycosides | 1 | 2014 | 10 | 0.230 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 4 | 0.230 |
Why?
|
| Amphotericin B | 1 | 2014 | 19 | 0.230 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2013 | 2 | 0.220 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 4 | 0.220 |
Why?
|
| Antifungal Agents | 1 | 2014 | 67 | 0.220 |
Why?
|
| Drug Combinations | 2 | 2017 | 50 | 0.190 |
Why?
|
| Drug Interactions | 2 | 2021 | 79 | 0.140 |
Why?
|
| Tablets | 1 | 2017 | 6 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 21 | 0.140 |
Why?
|
| Humans | 7 | 2021 | 28094 | 0.130 |
Why?
|
| Assertiveness | 1 | 2021 | 4 | 0.100 |
Why?
|
| Empathy | 1 | 2021 | 37 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2014 | 885 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2017 | 2377 | 0.090 |
Why?
|
| Communication | 1 | 2021 | 178 | 0.080 |
Why?
|
| Occupations | 1 | 2018 | 9 | 0.080 |
Why?
|
| Writing | 1 | 2018 | 14 | 0.080 |
Why?
|
| Feedback | 1 | 2018 | 33 | 0.080 |
Why?
|
| Education | 1 | 2018 | 33 | 0.070 |
Why?
|
| Male | 3 | 2021 | 13489 | 0.070 |
Why?
|
| Educational Measurement | 1 | 2018 | 127 | 0.070 |
Why?
|
| Learning | 1 | 2018 | 97 | 0.070 |
Why?
|
| Female | 3 | 2021 | 15153 | 0.070 |
Why?
|
| Students, Pharmacy | 1 | 2018 | 83 | 0.070 |
Why?
|
| Curriculum | 1 | 2018 | 291 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1013 | 0.060 |
Why?
|
| Amikacin | 1 | 2014 | 4 | 0.060 |
Why?
|
| Gentamicins | 1 | 2014 | 15 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 961 | 0.060 |
Why?
|
| Tobramycin | 1 | 2014 | 13 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 43 | 0.060 |
Why?
|
| Phosphorus | 1 | 2014 | 53 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 224 | 0.060 |
Why?
|
| Raltegravir Potassium | 1 | 2013 | 1 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2013 | 4 | 0.050 |
Why?
|
| Pyrrolidinones | 1 | 2013 | 3 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2013 | 3 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2013 | 8 | 0.050 |
Why?
|
| Half-Life | 1 | 2013 | 34 | 0.050 |
Why?
|
| Alkynes | 1 | 2013 | 7 | 0.050 |
Why?
|
| Ritonavir | 1 | 2013 | 11 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2013 | 14 | 0.050 |
Why?
|
| Pyridones | 1 | 2013 | 35 | 0.050 |
Why?
|
| Oxazines | 1 | 2013 | 19 | 0.050 |
Why?
|
| Piperazines | 1 | 2013 | 47 | 0.050 |
Why?
|
| Animals | 1 | 2017 | 10415 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 243 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 607 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 214 | 0.050 |
Why?
|
| Young Adult | 1 | 2018 | 2732 | 0.040 |
Why?
|
| Infant | 1 | 2014 | 1004 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2014 | 1146 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 523 | 0.040 |
Why?
|
| Risk Factors | 1 | 2014 | 2081 | 0.040 |
Why?
|
| Child | 1 | 2014 | 2242 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2546 | 0.040 |
Why?
|
| Adolescent | 1 | 2014 | 3121 | 0.030 |
Why?
|
| Adult | 1 | 2018 | 7739 | 0.030 |
Why?
|